Tag: Velaglucerase alfa

Without insurance, a single vial of Vpriv (velaglucerase alfa) has an approximate list price of nearly $1,500. As a treatment for the rare genetic disorder Gaucher disease, the annual cost can potentially exceed six figures, making the question of **how much does Vpriv cost?** a critical concern for patients and their families.

VPRIV (velaglucerase alfa) was approved by the U.S. Food and Drug Administration (FDA) in 2010 for long-term treatment of Type 1 Gaucher disease. For those asking what is the generic for VPRIV, it is important to understand that this medication, as a biologic, does not have a generic version in the traditional sense.

For patients with type 1 Gaucher disease, VPRIV is typically administered as a 60-minute intravenous infusion once every other week. However, the total time spent at an infusion center is often longer to account for patient assessment, medication preparation, and a crucial period of post-treatment monitoring by a healthcare professional.

First approved by the FDA in 2010, the medication known as VPRIV was originally manufactured by Shire plc. This article details the complex manufacturing history of VPRIV, explaining how it transitioned from its original developer to being produced by Takeda Pharmaceuticals today.

Approved by the FDA in 2010, Vpriv (velaglucerase alfa) has over a decade of real-world experience as a long-term enzyme replacement therapy (ERT). It is used to treat Type 1 Gaucher disease in adults and children ages 4 and older.